The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant
Open Access
- 13 September 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (9) , 2313
Abstract
Oral vaccines represent many advantages compared to standard vaccines. They hold a simple method of administration and manufacturing process. In addition to these, the way they can induce immune responses makes these a promising technology for the pharmaceutical industry and represents a new hope to society. Physiologically based pharmacokinetics (PBPK) has been used in support of drug development to predict the pharmacokinetics of the compound, considering the patient’s physiology. Despite PBPK studies now being widely used, there are very few models in the literature that support vaccine development. Therefore, the goal of this article was to determine how PBPK could support vaccine development. The first PBPK model for an oral vaccine using alpha-tocopherol as a vaccine adjuvant was built. LogP is the parameter that influences the delivery of alpha-tocopherol into the tissues more. Having a high LogP means it accumulates in adipose tissue and is slowly metabolized. The ideal formulation to include alpha-tocopherol in an oral vaccine would incorporate nanoparticles in a capsule, and the dosage of the compound would be 150 mg in a volume of 200 mL. This article aims to determine if alpha-tocopherol, as a well-known adjuvant for intramuscular injection vaccines, could be used as an adjuvant to oral vaccines. This model was built considering the conditions and requirements needed for designing an oral vaccine. This implies making sure the antigen and adjuvants reach the main target by overcoming the challenges of the gastrointestinal tract. The main parameters that would need to be included in a formulation using alpha-tocopherol as an adjuvant were determined.Keywords
Funding Information
- Fundo Europeu de Desenvolvimento Regional (FEDER) (IF/00092/2014/CP1255/CT0004)
- Fundação para a Ciência e a Tecnologia (FCT) (IF/00092/2014/CP1255/CT0004)
This publication has 49 references indexed in Scilit:
- This Kinetic, Bioavailability, and Metabolism Study of RRR-α-Tocopherol in Healthy Adults Suggests Lower Intake Requirements than Previous Estimates,The Journal of Nutrition, 2012
- Metrics for the Evaluation of Bioequivalence of Modified-Release FormulationsThe AAPS Journal, 2012
- Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsionExpert Review of Vaccines, 2012
- Optimizing vaccine developmentCellular Microbiology, 2011
- Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic ModellingClinical Pharmacokinetics, 2011
- A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditionsClinical Therapeutics, 2009
- MDR1genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic malesBritish Journal of Clinical Pharmacology, 2008
- Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administrationAdvanced Drug Delivery Reviews, 2008
- Cellular mechanisms of vitamin E uptake: relevance in α-tocopherol metabolism and potential implications for diseaseThe Journal of Nutritional Biochemistry, 2004
- Evaluation of Different Indirect Measures of Rate of Drug Absorption in Comparative Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1994